Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Vvax001 in HPV16-positive CIN3
NL-OMON55191Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Vvax001 in cervical intraepithelial neoplasia (CIN) and human papillomavirus infection, sponsored by University Medical Center Groningen. Primary endpoint: Clinical efficacy. Started Mar 2021; status: completed.
02
Drugs
Vvax001
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on NL-OMON55191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55191.